Baroldi Joseph 4
4 · IONIS PHARMACEUTICALS INC · Filed Mar 5, 2026
Insider Transaction Report
Form 4
Baroldi Joseph
EVP, Chief Business Officer
Transactions
- Sale
Common Stock
[F1]2026-03-03$79.36/sh−4,096$325,059→ 41,317 total - Exercise/Conversion
Common Stock
2026-03-03$56.78/sh+820$46,560→ 5,592 total(indirect: By Spouse) - Exercise/Conversion
Common Stock
2026-03-03$32.60/sh+879$28,655→ 6,471 total(indirect: By Spouse) - Sale
Common Stock
[F2][F3]2026-03-03$80.41/sh−2,088$167,892→ 4,383 total(indirect: By Spouse) - Sale
Common Stock
[F2]2026-03-03$81.01/sh−36$2,916→ 4,347 total(indirect: By Spouse) - Exercise/Conversion
Common Stock
2026-03-04$56.78/sh+238$13,514→ 4,585 total(indirect: By Spouse) - Sale
Common Stock
[F2]2026-03-04$80.00/sh−238$19,040→ 4,347 total(indirect: By Spouse) - Exercise/Conversion
Common Stock
2026-03-04$32.60/sh+201$6,553→ 4,548 total(indirect: By Spouse) - Sale
Common Stock
[F2]2026-03-04$80.00/sh−201$16,080→ 4,347 total(indirect: By Spouse) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−879→ 1,970 total(indirect: By Spouse)Exercise: $32.60From: 2023-01-03Exp: 2032-01-02→ Common Stock (879 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-04−201→ 1,769 total(indirect: By Spouse)Exercise: $32.60From: 2023-01-03Exp: 2032-01-02→ Common Stock (201 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-03−820→ 4,104 total(indirect: By Spouse)Exercise: $56.78From: 2022-01-04Exp: 2028-01-03→ Common Stock (820 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-03-04−238→ 3,866 total(indirect: By Spouse)Exercise: $56.78From: 2022-01-04Exp: 2028-01-03→ Common Stock (238 underlying)
Footnotes (3)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.
- [F2]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting persons spouse on November 25, 2025.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.94 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Joseph T. Baroldi|2026-03-05